Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma
Trial details
- Registry ID
- NCT04752696
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as Nal-IRI; Onivyde
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal AdenocarcinomaNCT04752696 | Cardiff Oncology | Phase 2 | Terminated | 2024-12-24Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |